{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:05:38Z","timestamp":1784930738936,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104798","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:11:43Z","timestamp":1778818303000},"page":"104798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Overall survival outcomes in occult primary breast cancer"],"prefix":"10.1016","volume":"88","author":[{"given":"Nara L.","family":"Tashjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy C.","family":"Boughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0863-8258","authenticated-orcid":false,"given":"Mara A.","family":"Piltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104798_bib1","series-title":"Bland and Copeland's the breast","first-page":"792","article-title":"Unknown primary presenting with axillary lymphadenopathy","author":"Lathrop","year":"2024"},{"key":"10.1016\/j.breast.2026.104798_bib2","series-title":"NCCN: breast cancer screening and diagnosis","author":"Network","year":"2025"},{"key":"10.1016\/j.breast.2026.104798_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.rcl.2020.09.004","article-title":"Magnetic resonance imaging in screening of breast cancer","volume":"59","author":"Gao","year":"2021","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.breast.2026.104798_bib4","article-title":"Comparison of the sensitivity of mammography, ultrasound, magnetic resonance imaging and combinations of these imaging modalities for the detection of small (<\/=2 cm) breast cancer","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.breast.2026.104798_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejso.2009.09.007","article-title":"Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review","volume":"36","author":"de Bresser","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.breast.2026.104798_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.amjsurg.2019.11.023","article-title":"Treatment for occult breast cancer: a propensity score analysis of the National Cancer Database","volume":"220","author":"Tsai","year":"2020","journal-title":"Am J Surg"},{"key":"10.1016\/j.breast.2026.104798_bib7","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1245\/s10434-017-5928-x","article-title":"Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: analysis of the national cancer database","volume":"24","author":"Hessler","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2026.104798_bib8","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1245\/s10434-016-5104-8","article-title":"Optimal surgical management for occult breast carcinoma: a meta-analysis","volume":"23","author":"Macedo","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2026.104798_bib9","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1200\/JCO.2008.18.9845","article-title":"Improved survival for stage IV melanoma from an unknown primary site","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104798_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1677139","article-title":"Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results","volume":"8","author":"Gambichler","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.breast.2026.104798_bib11","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1245\/s10434-014-3679-5","article-title":"Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease","volume":"21","author":"van der Ploeg","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2026.104798_bib12","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the national cancer database for Outcomes research: a review","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104798_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/XCS.0000000000001214","article-title":"American College of Surgeons Cancer Program annual report from 2021 participant user file","volume":"240","author":"Habermann","year":"2025","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.breast.2026.104798_bib14","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1245\/s10434-020-08863-2","article-title":"Axillary downstaging in occult primary breast cancer after neoadjuvant chemotherapy","volume":"28","author":"Botty Van den Bruele","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2026.104798_bib15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10549-024-07500-w","article-title":"Trends in management and related outcomes for occult primary breast cancer","volume":"209","author":"LaBella","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104798_bib16","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.breast.2026.104798_bib17","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1245\/s10434-020-08900-0","article-title":"Oncologic outcomes of sentinel lymph Node surgery after neoadjuvant chemotherapy for Node-Positive breast cancer","volume":"27","author":"Piltin","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2026.104798_bib18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jamaoncol.2024.0578","article-title":"Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy","volume":"10","author":"Montagna","year":"2024","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104798_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.breast.2026.104798_bib20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jso.23644","article-title":"Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: a nationwide retrospective study","volume":"110","author":"Sohn","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.breast.2026.104798_bib21","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.2147\/CMAR.S169019","article-title":"Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study","volume":"10","author":"Ge","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.breast.2026.104798_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12885-025-13657-4","article-title":"Proteomic profiling reveals biological processes and biomarkers involved in the pathogenesis of occult breast cancer","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2026.104798_bib23","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104798_bib24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-017-4162-3","article-title":"Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database","volume":"163","author":"Roberts","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104798_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5152\/ejbh.2019.4414","article-title":"Impact of number of positive lymph nodes and lymph node ratio on survival of women with node-positive breast cancer","volume":"15","author":"Tonellotto","year":"2019","journal-title":"Eur J Breast Health"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:30:02Z","timestamp":1784928602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":25,"alternative-id":["S0960977626001086"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104798","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall survival outcomes in occult primary breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104798"}}